VIP Peptide Results: Week-by-Week Timeline (2026)

Weeks 1-2: Acute Vascular Effects, Little Else

What the published research describes:

Acute vasodilation following first doses — small reductions in blood pressure and increased cardiac output were documented in the original pulmonary hypertension trial (Petkov et al., 2003).

Receptor-level cAMP elevation is essentially immediate; downstream anti-inflammatory signaling begins within hours.

30-day intranasal protocols in CIRS report biomarker movement (C4a, TGF-B1) measured at the protocol endpoint, not in the first two weeks.

What community reports typically describe:

Day one: Transient hypotension, mild dizziness on standing, occasional facial flushing — all consistent with VIP's vasodilator profile.

Mild headache in the first several days, typically reported as resolving within a week.

Nasal irritation or burning with the intranasal route, particularly during initial sprays.

Loose stools in some users — VIP affects GI motility through enteric nervous system signaling.

No clear cognitive or inflammatory shifts in the first week. Community reports of "feeling something" this early are usually vascular.

What community reports do NOT typically describe at this stage:

Resolution of long-standing symptoms.

Measurable changes in CIRS markers (C4a, TGF-B1, MMP-9) — these labs are typically rechecked at 30 days, not 2 weeks.

Cognitive improvement.

Sleep architecture changes.

Realistic framing: The first two weeks are largely about tolerating the vascular profile and confirming that prerequisites (in CIRS contexts, mold remediation and MARCoNS clearance) are actually complete. Subjective improvement this early is uncommon and is not the time to evaluate whether the protocol is "working."

Weeks 3-4: Early Inflammatory and Cognitive Shifts

The original Shoemaker intranasal CIRS protocol uses a 30-day initial endpoint. At day 30, biomarker shifts (reduced C4a, reduced TGF-B1) and quality-of-life improvements have been documented in patients who completed all prerequisites.

VIP's effects on regulatory T cell populations in animal models accumulate over weeks of exposure (Gonzalez-Rey et al., 2005).

Hormone restoration (estradiol, testosterone) was reported alongside biomarker shifts in the same 30-day window in CIRS patients.

Some CIRS users report reductions in brain fog, post-exertional fatigue, or food sensitivity flares by the end of the first month.

Sleep is the most commonly mentioned subjective shift — community forums describe deeper or more consolidated sleep, sometimes with vivid dreaming as VIP's circadian-regulatory effects accumulate (Aton et al., 2005).

Subcutaneous users (without CIRS context) describe a wider spread of experiences — some describe a calming or anti-inflammatory feel, others describe nothing at all.

What community reports describe inconsistently:

Energy. Some users describe more, some less. Both are biologically plausible — VIP's anti-inflammatory effects could reduce inflammation-driven fatigue, while its vasodilation can produce mild lightheadedness in some people.

Mood. Community reports range from improvements to no change. There is no controlled evidence on this.

Realistic framing: Weeks 3-4 are the earliest window in which the Shoemaker literature reports objective changes — and that's specifically in CIRS patients with the prerequisite biology and labs. Outside that context, community reports are wider and lower-confidence.

Weeks 5-8: Sustained Anti-Inflammatory Pattern

The standard subcutaneous community protocol cycles 8 weeks on / 8 weeks off. There is no controlled clinical data isolating week 5-8 endpoints in CIRS, but extended intranasal protocols continue past day 30 with progressive biomarker improvement reported in clinical practice.

Animal models of autoimmune and inflammatory disease show progressive Treg expansion and Th1/Th17 suppression with sustained VIP exposure.

Stabilization of whatever shifts started in weeks 3-4. CIRS forum reports often describe the second month as where improvements feel "more durable" rather than the larger initial drop.

Continued sleep changes — both in quality and in circadian regularity. The mechanistic basis (VIP's role in synchronizing the suprachiasmatic nucleus) is well-established in animal work but remains indirect for humans.

For CIRS patients with GI involvement, community reports describe gradual reduction in bloating, food reactivity, or motility issues over this window.

Subcutaneous users describe tapering of the day-one vascular effects — most describe these as mostly absent by week 5-6.

Energy and exercise tolerance. Some users describe noticeable gains around the 6-week mark; others see no change.

Cognition. CIRS patients with documented neuroinflammation describe more durable improvements; users without that baseline report less.

Realistic framing: Weeks 5-8 are where most community CIRS reports describe the protocol "settling in." If you have made it this far without prerequisites being complete (in CIRS contexts), this is also where some people describe symptom worsening or stalled improvement — a common reason to revisit prior protocol steps rather than push the dose.

Ready to compare vendors? See the best VIP sources page, or browse all coupon codes for up to 50% off.

Weeks 9-12+: Extended Protocols and Structural Changes

The Shoemaker CIRS protocol does not end at 30 days for many patients. Extended intranasal regimens at 6-8 sprays daily for 12+ weeks are described in the published literature on grey matter restoration.

Extended intranasal VIP therapy in CIRS patients was associated with restoration of grey matter volume in multiple brain nuclei measured by NeuroQuant volumetric MRI (Shoemaker et al., 2014). This is the longest-term human imaging data available for VIP and remains specific to a CIRS context.

The grey matter findings should be read with the single-research-group caveat: most VIP-CIRS data comes from Shoemaker's clinical group. Independent replication is limited.

CIRS patients on extended intranasal protocols describe continued, slower-paced improvement — fewer crashes, more cognitive stamina, gradual reduction in sensory overload.

Subcutaneous users at 12+ weeks usually cycle off per the standard 8-on / 8-off protocol; reports of continued benefit during the off-cycle are common but uncontrolled.

A subset of users describes plateau by week 10-12 — improvement holding steady rather than continuing to compound.

What is rarely described in community reports:

Dramatic late-cycle effects appearing only at month 3+. Most users describe the bulk of subjective change happening earlier, with the back half being consolidation rather than new gains.

Realistic framing: The 12+ week window is where the evidence base contracts to one research group's clinical observations. Community reports broadly align with the direction of published findings (gradual, cumulative, biased toward the inflammatory and neurological domains), but the strength of evidence drops considerably outside the original CIRS literature.

Post-Cycle: Washout and Persistence

The standard subcutaneous protocol cycles 8 weeks on, 8 weeks off. The intranasal CIRS protocols are typically followed by physician-directed maintenance dosing, taper, or extended cycles depending on biomarker response.

Limited published data exists on persistence of effect after VIP discontinuation. The Shoemaker grey matter work was measured during ongoing treatment, not after stopping.

VIP's half-life is short (minutes in serum), so any sustained effect requires either ongoing dosing or downstream changes (Treg populations, inflammatory marker normalization, structural tissue changes) that outlast the peptide itself.

CIRS patients describe a mix of outcomes: some maintain improvements off-cycle, some experience gradual symptom return, some cycle indefinitely under physician supervision.

Subcutaneous users often describe a relatively smooth taper at the 8-week off-cycle mark, with the day-one vascular effects fully gone by then.

A common report: improvements that built slowly over 8-12 weeks tend to fade more slowly than they came on if the underlying inflammatory driver (mold exposure, MARCoNS, etc.) has been addressed.

Realistic framing: Post-cycle persistence depends heavily on whether the underlying inflammation has been resolved. VIP appears to act as a modulator on top of the biology — it does not eliminate the underlying triggers. If the trigger is still present, the off-cycle period tends to reveal that.

Variability Factors Specific to VIP

Why two users on the same protocol can have radically different timelines:

CIRS Stage and Prerequisite Completion

The Shoemaker protocol has explicit prerequisites — removal from mold exposure, cholestyramine binder phase, MARCoNS eradication, correction of inflammatory markers. Community reports of poor VIP response very often trace back to incomplete prerequisites. Starting VIP with active mold exposure or persistent MARCoNS colonization can worsen inflammatory symptoms in published clinical experience. The peptide is the last step, not the first.

Mold Load and Environmental Recolonization

Even after remediation, residual environmental exposure — a contaminated workplace, a previously affected vehicle, an untested second residence — can stall VIP responses. Forum reports of "started VIP, felt great for two weeks, then crashed" frequently resolve to a missed environmental source.

Route of Administration

Intranasal delivery is the route used in the published CIRS literature. Subcutaneous is the route described in research-peptide community protocols. The two routes have different pharmacokinetics, different CNS exposure, and different evidence bases. Comparing intranasal-protocol timelines to subcutaneous experience (or vice versa) is a common source of confusion.

Stack with Other CIRS Protocol Steps

CIRS users running VIP on top of cholestyramine, low-amylose diet, MARCoNS protocols, and physician-directed hormone work have a different timeline than someone running VIP alone. The Shoemaker biomarker shifts were documented in patients running the full protocol, not VIP in isolation.

Baseline Inflammation

VIP's anti-inflammatory mechanism produces more measurable effects in users with elevated baseline inflammation. Users without documented inflammation have less to "fix" — both biomarker movement and subjective changes tend to be smaller.

Individual Receptor Genetics

VPAC1 and VPAC2 receptor expression varies between individuals. There is no commercial test for this. Pharmacogenomic variability is one plausible explanation for the wide spread in community reports, but it remains an inference rather than a confirmed mechanism.

What Community Reports Show vs What Research Has Documented

Honesty about the evidence base matters here. The peptide is widely discussed in CIRS, mold-illness, mast-cell-activation, and post-viral communities. Not all of those discussions are anchored to published evidence.

Where community reports and published research align:

Day-one vascular effects (hypotension, flushing, mild headache).

30-day biomarker improvement in CIRS patients with completed prerequisites (Shoemaker clinical data).

Sleep and circadian shifts (mechanistic data from animal SCN work, community subjective reports).

Anti-inflammatory direction of effect (animal Treg and macrophage data, community symptom reports).

Where community reports outrun the published evidence:

VIP for "general anti-aging" or "immune boosting" without documented inflammation. No published evidence supports this use.

VIP for post-COVID brain fog outside hospitalized critical-illness contexts. The Youssef IV aviptadil RCT was in critically ill patients on respiratory failure (Youssef et al., 2022) — that evidence base does not transfer to outpatient long-COVID protocols.

VIP as a standalone mast-cell-activation treatment. Mechanistic plausibility exists; controlled human evidence does not.

VIP for general cognitive enhancement in healthy users. The grey matter data is in CIRS patients with documented baseline atrophy, not in healthy brains.

Single-research-group limitation: Most VIP-CIRS published work originates from Shoemaker's clinical group. Independent replication of the grey matter and biomarker findings remains limited. This does not invalidate the work — but it does mean readers and clinicians should treat the published timelines as findings that need broader confirmation, not as established clinical guidelines.

What VIP Does NOT Typically Do

Equally important — what the timeline does not promise, regardless of how long the protocol runs:

It does not produce stimulant-like effects. Day-one experience is vascular, not energizing. Users expecting a noticeable lift within hours often abandon the protocol prematurely.

It does not replace mold remediation. The Shoemaker clinical literature is explicit on this point. VIP introduced into ongoing biotoxin exposure can worsen inflammation.

It does not "cure" CIRS. Even the strongest published outcomes describe biomarker normalization and grey matter volume restoration — not elimination of underlying susceptibility to re-exposure.

It does not have published cognitive enhancement data in healthy users. The grey matter restoration findings are in patients with documented atrophy, not in baseline-normal brains.

It does not have controlled long-COVID outpatient evidence. Despite community use for post-viral brain fog, the only RCT-grade aviptadil evidence is in critically ill hospitalized patients.

It does not work uniformly across the community. Wide variability in reported outcomes is the norm, not the exception. Anyone presenting VIP as predictably effective for any indication is overstating the data.

How to Track VIP Progress

For users running VIP under physician supervision (especially in CIRS contexts), tracking is more productive than relying on subjective impression alone.

Biomarkers commonly monitored in CIRS protocols:

C4a (complement activation)

TGF-B1 (transforming growth factor beta-1)

MMP-9 (matrix metalloproteinase-9)

VEGF, MSH (typically tracked across full Shoemaker protocol)

Lipase (safety marker — significant elevation can warrant dose adjustment)

Functional measures community users describe tracking:

Sleep quality and consistency (consumer wearables, sleep diaries)

Cognitive function (consistent self-administered tests, work performance)

GI symptom diaries for users with CIRS-related gut involvement

Resting blood pressure and heart rate (vasodilator profile)

Imaging (CIRS clinical contexts):

NeuroQuant volumetric MRI before and after extended protocols, where indicated by clinical findings.

Documentation matters more than memory. Users who track baselines tend to evaluate response more accurately than users relying on retrospective impression.

When Community Reports Suggest the Protocol Isn't Working

Patterns that frequently precede non-response or worsening, based on forum reports and published clinical commentary:

Starting VIP without full prerequisite completion (CIRS contexts).

Ongoing residual mold exposure (workplace, vehicle, secondary residence).

MARCoNS recolonization not retested.

Wrong route for the indication (subcutaneous protocol applied to a CIRS context where intranasal is the studied route).

Severely elevated lipase or other safety-marker signal — the Shoemaker protocol calls for dose adjustment rather than continuation.

Fundamental expectation mismatch — expecting stimulant-style acute effects from a slow-acting anti-inflammatory neuropeptide.

In all these cases, the published clinical experience favors revisiting prerequisites rather than escalating the dose.